In June 2004, Genomics Collaborative had been acquired by CA based SeraCare Life Sciences (NASDAQ:SRLS.) - itself previously an SBIR involved firm. A functional genomics company with a track record of collaborative endeavor, Genomics Collaborative, Inc. (GCI), had developed expertise in applying the science of human genetics to drug and diagnostic discovery decisions. The Companys approach links human genes, proteins, and clinical outcomes through proprietary technology platforms. GCIs state-of-the-art technology offers a highly efficient method to validate genomics-based drug and diagnostic targets, and has already been validated through partnerships with more than 30 pharmaceutical and biotechnology companies. The Company has prospectively enrolled over 120,000 patients in Global Repository, and patient recruitment continues in many disease states. In 2007, with SeraCare in some trouble, major assets of Genomics Collaborative were sold to BioServe - management of which indicate intent fully to integrate Genomics Collaborative into its operations expanding its pre-clinical service offerings and for drug discovery and development, allowing the company to offer a platform that takes biomaterial to validated data. The combined platform included DNA and RNA purification reagents, DNA sequencing, oligonucleotide synthesis, and genotyping services for studies of a variety of diseases, including cardiovascular disease, inflammatory disorders, several common cancers, and others.
